Skip to main content
. 2024 Apr 17;8(2):e194–e201. doi: 10.1055/s-0044-1785525

Fig. 3.

Fig. 3

Bleeding treatment of patients with hemophilia A. aPCC, activated prothrombin complex concentrate; FVIII, coagulation factor VIII; rFVIIa, recombinant activated factor VII; TMA, thrombotic microangiopathy.